Preclinical development and clinical safety assessment of a synthetic peptide conjugate enabling endogenous antibody binding to promote innate receptor engagement

Preclinical development and clinical safety assessment of a synthetic peptide conjugate enabling endogenous antibody binding to promote innate receptor engagement

Peptide-based vaccines can be used to deliver tumor-specific antigens to dendritic cells (DCs), leading to tumor-directed T cell responses. We previously developed a peptide-peptide conjugate technology enabling in vivo cross-linking of pre-existing tetanus toxin-directed antibodies, facilitating an...

Full description

Saved in:
Bibliographic Details
Main Authors: Erika A.K. Fletcher, Robert A. Cordfunke, Aikaterini Nasi, Gunilla Törnqvist, Rob R.P.M. Valentijn, Anna Bergqvist, Marita Westhrin, Wenche Rasch, Frida Lindqvist, Inken Dillmann, Martin Lord, Neanke Bouwman, Jacques J. Neefjes, Kees L.M.C. Franken, Stephanie McArdle, Murrium Ahmad, Silvia Johansson, Ferry Ossendorp, Michael Haggman, Maria Lampinen, Gustav Ullenhag, Sam Ladjevardi, Justyna Leja-Jarblad, Wolfgang Lilleby, Jan Wouter Drijfhout, Sara M. Mangsbo
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:Molecular Therapy: Oncology
Subjects:
MT: Regular Issue
prostate cancer
peptide-conjugate vaccine
tetanus toxoid
immunotherapy
dendritic cells
Online Access:http://www.sciencedirect.com/science/article/pii/S2950329925000232
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2950329925000232

Similar Items